Recently, increased UCP2 expression following rosiglitazone treatment in melanoma cell lines promoted antitumor immunity and induced the reprogramming of the cytokine profile secreted by tumor-infiltrating T cells [117]. The gene discussed is UCP2; the disease is melanoma.